Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Summary

This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.

Timeline

Start

2021-06-16

Primary completion

2025-04-14

Completion

2025-04-14

Outcome

Outcome not reported

Stopped (Business): “Business objectives have changed”

Publications

• Lunn-Halbert MC, Laszlo GS, Erraiss S, Orr MT, Jessup HK, Thomas HJ, Chan H, Jahromi MA, Lloyd J, Cheung AF, Chang GP, Dichwalkar T, Fallon D, Grinberg A, Rodriguez-Arboli E, Lim SYT, Kehret AR, Huo J, Cole FM, Scharffenberger SC, Walter RB. Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET(R) CC-96191. Cancers (Basel). 2024 Feb 22;16(5):877. doi: 10.3390/cancers16050877.

Drugs

Indications